Genmab A/S (CPH:GMAB)
2,185.00
+21.00 (0.97%)
At close: Jan 16, 2026
Genmab Revenue
Genmab had revenue of $1.02B USD in the quarter ending September 30, 2025, with 25.25% growth. This brings the company's revenue in the last twelve months to $3.47B, up 18.00% year-over-year. In the year 2024, Genmab had annual revenue of $3.00B with 23.13% growth.
Revenue (ttm)
$3.47B
Revenue Growth
+18.00%
P/S Ratio
5.50
Revenue / Employee
$1.29M
Employees
2,682
Market Cap
134.59B DKK
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.00B | 564.17M | 23.13% |
| Dec 31, 2023 | 2.44B | 351.45M | 16.83% |
| Dec 31, 2022 | 2.09B | 800.56M | 62.19% |
| Dec 31, 2021 | 1.29B | -372.56M | -22.45% |
| Dec 31, 2020 | 1.66B | 854.43M | 106.10% |
| Dec 31, 2019 | 805.32M | 340.75M | 73.35% |
| Dec 31, 2018 | 464.57M | 83.37M | 21.87% |
| Dec 31, 2017 | 381.20M | -144.81M | -27.53% |
| Dec 31, 2016 | 526.01M | 195.32M | 59.07% |
| Dec 31, 2015 | 330.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 315.60B |
| Coloplast | 27.87B |
| H. Lundbeck | 24.08B |
| Demant | 22.59B |
| GN Store Nord | 17.12B |
| Zealand Pharma | 9.16B |
| Bavarian Nordic | 6.89B |
| ALK-Abelló | 6.08B |
Genmab News
- 9 hours ago - Genmab (GMAB) Phase 3 Trial Results: Impact and Future Outlook - GuruFocus
- 9 hours ago - Genmab's (GMAB) Epcoritamab Shows Promise in DLBCL Trial - GuruFocus
- 10 hours ago - Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma - Seeking Alpha
- 10 hours ago - AbbVie (ABBV) and Genmab Advance Epcoritamab Trials for Lymphoma - GuruFocus
- 11 hours ago - Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study - Reuters
- 11 hours ago - Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Business Wire
- 11 hours ago - Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - GlobeNewsWire
- 2 days ago - Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha